Core Insights - The National Medical Products Administration (NMPA) held a meeting to convey the spirit of the 20th Central Committee's Fourth Plenary Session, focusing on drug regulation reforms and safety measures [1] Group 1: Leadership and Governance - The meeting emphasized the importance of strengthening the leadership and construction of the Party, ensuring adherence to the "two establishments" and "two safeguards" [1] - It highlighted the need for consistent implementation of General Secretary Xi Jinping's directives on drug regulation and the Party's decision-making regarding drug supervision [1] Group 2: Drug Safety Regulation - There is a focus on enhancing the entire chain of drug safety regulation, improving the drug safety responsibility system, and establishing a risk consultation mechanism [1] - The NMPA aims to strengthen oversight in key areas and combat illegal activities to maintain drug safety and stability [1] Group 3: Regulatory Reforms - The NMPA plans to deepen drug regulation reforms by enhancing communication throughout the entire process of clinical trials, registration, inspection, and review [1] - Support for the development of innovative drugs and medical devices is a priority [1] Group 4: Collaborative Development - The meeting stressed the importance of promoting the coordinated development of the "three medicines" (medical insurance, medical services, and pharmaceuticals) [1] - Efforts will be made to optimize drug procurement and support the innovation and inheritance of traditional Chinese medicine [1]
国家药监局：着力强化药品安全全链条监管 全力支持创新药和医疗器械发展
Di Yi Cai Jing·2025-10-24 12:34